Elotuzumab causes activation of NK cells by SLAMF7 ligation to exert its anti-myeloma function. Moreover, it also results in antibody-dependent cellular cytotoxicity. The frequent adverse event recorded was lymphopenia. The gene discussed is SLAMF7; the disease is lymphopenia.